MX2018005242A - Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. - Google Patents
Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos.Info
- Publication number
- MX2018005242A MX2018005242A MX2018005242A MX2018005242A MX2018005242A MX 2018005242 A MX2018005242 A MX 2018005242A MX 2018005242 A MX2018005242 A MX 2018005242A MX 2018005242 A MX2018005242 A MX 2018005242A MX 2018005242 A MX2018005242 A MX 2018005242A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulations
- compounds
- ion channel
- inhibitory compounds
- directed towards
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención está dirigida a entidades químicas nuevas que inhiben principalmente los canales de calcio tipo T de humano y regulan diferencialmente otros canales iónicos clave para controlar la excitabilidad celular y la actividad neuronal anormal, involucrada particularmente en el desarrollo y el mantenimiento de dolor persistente o crónico y/o trastornos neurológicos. Estos compuestos nuevos son útiles en el tratamiento y la prevención de trastornos y enfermedades neurológicas y psiquiátricas en las que estos canales iónicos están involucrados. La invención también está dirigida a formulaciones farmacéuticas que comprenden estos compuestos y a los usos de estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562254564P | 2015-11-12 | 2015-11-12 | |
PCT/US2016/061918 WO2017083867A1 (en) | 2015-11-12 | 2016-11-14 | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005242A true MX2018005242A (es) | 2019-03-18 |
Family
ID=58696184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005242A MX2018005242A (es) | 2015-11-12 | 2016-11-14 | Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. |
Country Status (17)
Country | Link |
---|---|
US (1) | US10562857B2 (es) |
EP (1) | EP3340988A4 (es) |
JP (1) | JP6790094B2 (es) |
KR (1) | KR102217524B1 (es) |
CN (1) | CN108289886B (es) |
AU (1) | AU2016353446B2 (es) |
BR (1) | BR112018009439B1 (es) |
CA (1) | CA3004448A1 (es) |
HK (1) | HK1254407A1 (es) |
IL (1) | IL259199B (es) |
MX (1) | MX2018005242A (es) |
NZ (1) | NZ742033A (es) |
PH (1) | PH12018501000A1 (es) |
RU (1) | RU2746188C2 (es) |
SG (1) | SG11201803475YA (es) |
WO (1) | WO2017083867A1 (es) |
ZA (1) | ZA201803739B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018300980A1 (en) * | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
US11149022B2 (en) | 2017-10-17 | 2021-10-19 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
WO2019126559A1 (en) | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
CN110294717B (zh) * | 2018-03-21 | 2021-01-19 | 湖南加法检测有限公司 | 农药全组分中2,2-二取代环丁酮杂质及其衍生物、制备方法与应用 |
CN108658933A (zh) * | 2018-07-13 | 2018-10-16 | 南京大学 | 一种二芳基并噻吩型或二芳基硫醚型氘代烷基的制备方法 |
US11744825B2 (en) | 2018-08-28 | 2023-09-05 | Afasci, Inc. | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds |
EP3962483A4 (en) * | 2019-05-02 | 2023-01-25 | Merck Sharp & Dohme LLC | ALLOSTERIC SPIROPIPERIDINE MODULATORS OF NICOTINE ACETYLCHOLINE RECEPTORS |
WO2021007487A1 (en) | 2019-07-11 | 2021-01-14 | Praxis Precision Medicines, Inc. | Formulations of t-type calcium channel modulators and methods of use thereof |
AU2021263804A1 (en) * | 2020-04-29 | 2023-01-19 | Praxis Precision Medicines, Inc. | Methods of use of T-type calcium channel modulators |
CN112574085A (zh) * | 2020-12-18 | 2021-03-30 | 南通药明康德医药科技有限公司 | 一种5-氨基-2-氮杂螺[3.4]辛烷-2-羧酸叔丁酯的制备方法 |
WO2023150703A2 (en) * | 2022-02-03 | 2023-08-10 | Praxis Precision Medicines, Inc. | Methods of treatment using t-type calcium channel modulators |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL126003A0 (en) | 1996-04-10 | 1999-04-11 | Hoechst Marion Roussel Inc | Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors |
US20100222387A1 (en) | 2005-06-23 | 2010-09-02 | Barrow James C | 3-Fluoro-Piperidine T-Type Calcium Channel Antagonists |
EP1901746B1 (en) * | 2005-06-29 | 2013-02-20 | Merck Sharp & Dohme Corp. | 4-fluoro-piperidine t-type calcium channel antagonists |
DE102005030231B4 (de) | 2005-06-29 | 2007-05-31 | Forschungszentrum Karlsruhe Gmbh | Verfahren zum Aufbringen einer hochtemperaturgeeigneten FeCrAl-Schutzschicht, Hüllrohr mit einer derartig aufgebrachten Schutzschicht und Verwendung eines solchen Hüllrohrs |
JP5440496B2 (ja) * | 2007-06-15 | 2014-03-12 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 置換2−[2−(フェニル)エチルアミノ]アルカンアミド誘導体ならびにナトリウムおよび/またはカルシウムチャネル調節剤としてのこれらの使用 |
US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
WO2012047703A2 (en) * | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
EP2685824A4 (en) | 2011-03-17 | 2014-09-10 | Merck Sharp & Dohme | INDOLE DERIVATIVES USEFUL AS CCR2ANTAGONISTS |
US8993757B2 (en) | 2011-09-22 | 2015-03-31 | Merck Sharp & Dohme B.V. | N-piperidin-4-yl derivatives |
LT2820008T (lt) | 2012-03-02 | 2017-06-12 | Genentech, Inc. | Amido spirociklinio amido ir sulfonamido dariniai |
KR101556318B1 (ko) * | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체 |
CN105358545A (zh) * | 2013-07-03 | 2016-02-24 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
JP2017001954A (ja) | 2013-11-08 | 2017-01-05 | 石原産業株式会社 | 含窒素飽和複素環化合物 |
-
2016
- 2016-11-14 WO PCT/US2016/061918 patent/WO2017083867A1/en active Application Filing
- 2016-11-14 KR KR1020187013376A patent/KR102217524B1/ko active IP Right Grant
- 2016-11-14 RU RU2018121288A patent/RU2746188C2/ru active
- 2016-11-14 JP JP2018523749A patent/JP6790094B2/ja active Active
- 2016-11-14 CA CA3004448A patent/CA3004448A1/en active Pending
- 2016-11-14 US US15/772,365 patent/US10562857B2/en active Active
- 2016-11-14 EP EP16865245.1A patent/EP3340988A4/en active Pending
- 2016-11-14 CN CN201680066520.XA patent/CN108289886B/zh active Active
- 2016-11-14 NZ NZ742033A patent/NZ742033A/en unknown
- 2016-11-14 BR BR112018009439-0A patent/BR112018009439B1/pt active IP Right Grant
- 2016-11-14 SG SG11201803475YA patent/SG11201803475YA/en unknown
- 2016-11-14 MX MX2018005242A patent/MX2018005242A/es unknown
- 2016-11-14 AU AU2016353446A patent/AU2016353446B2/en active Active
-
2018
- 2018-05-08 PH PH12018501000A patent/PH12018501000A1/en unknown
- 2018-05-08 IL IL259199A patent/IL259199B/en unknown
- 2018-06-06 ZA ZA2018/03739A patent/ZA201803739B/en unknown
- 2018-10-22 HK HK18113486.4A patent/HK1254407A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20180312471A1 (en) | 2018-11-01 |
AU2016353446B2 (en) | 2022-05-19 |
ZA201803739B (en) | 2019-04-24 |
PH12018501000A1 (en) | 2019-01-28 |
NZ742033A (en) | 2022-11-25 |
AU2016353446A1 (en) | 2018-05-24 |
IL259199A (en) | 2018-07-31 |
KR102217524B1 (ko) | 2021-02-19 |
US10562857B2 (en) | 2020-02-18 |
EP3340988A1 (en) | 2018-07-04 |
RU2018121288A (ru) | 2019-12-16 |
JP2018533593A (ja) | 2018-11-15 |
IL259199B (en) | 2022-03-01 |
CN108289886A (zh) | 2018-07-17 |
WO2017083867A1 (en) | 2017-05-18 |
CN108289886B (zh) | 2022-01-28 |
JP6790094B2 (ja) | 2020-11-25 |
BR112018009439A2 (pt) | 2018-12-04 |
KR20180074705A (ko) | 2018-07-03 |
SG11201803475YA (en) | 2018-05-30 |
EP3340988A4 (en) | 2019-05-15 |
CA3004448A1 (en) | 2017-05-18 |
HK1254407A1 (zh) | 2019-07-19 |
BR112018009439B1 (pt) | 2023-12-12 |
RU2746188C2 (ru) | 2021-04-08 |
RU2018121288A3 (es) | 2020-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501000A1 (en) | Ion channel inhibitory compounds, pharmaceutical formulations and uses | |
PH12016501463B1 (en) | Diaryl macrocycles as modulators of protein kinases | |
MX2022003323A (es) | Polinucleotidos dirigidos al sistema nervioso central. | |
MX2017003624A (es) | Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas. | |
MX2019012818A (es) | Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. | |
MX2020004183A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
EP3429605A4 (en) | THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM | |
MX2017011000A (es) | Compuestos de pirazol sustituidos como inhibidores de serina proteasa. | |
MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
MX2017005282A (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
AU2014212471A8 (en) | Cystathionine beta-synthase enzyme for treatment of homocystinuria | |
MX2018004220A (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo. | |
MX2017014715A (es) | Benzamidas sustituidas y metodos para utilizarlas. | |
MX2020005545A (es) | Compuestos para el tratamiento de trastornos neuromusculares. | |
MX2022006862A (es) | Inhibidores duales de magl y faah. | |
MX2018004217A (es) | Tetrahidropiranilsulfonas sustituidas con pirazolilo. | |
WO2021257697A8 (en) | Compounds and methods for blocking apoptosis and inducing autophagy | |
WO2019165158A8 (en) | Il-6 inhibitors and methods of treatment | |
MX2017012188A (es) | Inhibidores de beta-secretasa 1 (bace1). | |
MX2016013451A (es) | Heterociclilsulfonas arilo sustituidas. | |
PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
MX2021005334A (es) | Compuestos quimicos. | |
GB2553686A8 (en) | Ethynylxanthines, preparation and use as calcium ion channel modulators | |
MX2020005471A (es) | Compuestos para el tratamiento de trastornos neuromusculares. |